Ann: Annual Report to shareholders, page-20

Absolute snooze fest this company at the moment, total failure in investor relations. Why no mention of EAS / Ed Sugar in Annual Report or presentations ? What are they doing to earn their options ? Did they play a role in the new director's appointment ? This company needs capital to execute the proposed strategy, stop tap dancing and announce a plan that the market will buy.
I have followed the ResApp soap opera play out and find it incredible that Pfizer is paying $175 M+ for a diagnostic algorithm that is unreliable and inconsistent in their own clinical trials, let alone expected to work in the multitude of different phones manufactured around the world and RSH sits at a market cap $31 M and looking like sliding back to 3 c share price, heaven forbid there is any trading.
Seriously lift your bloody game.